Lead Product(s) : Vosilasarm
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABCS
Details : EP0062 (vosilasarm) is an oral, non-steroidal, selective androgen receptor modulator (SARM) currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer.
Product Name : EP0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2022
Lead Product(s) : Vosilasarm
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vosilasarm
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ellipses Pharma
Deal Size : Undisclosed
Deal Type : Divestment
Radius Health Divests RAD 140 Program to Ellipses Pharma
Details : Under the agreement, Ellipses Pharma will be responsible for the clinical development and commercialization of RAD 140. Radius will be entitled to receive royalties on the program as it advances with Ellipses.
Product Name : RAD140
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 10, 2020
Lead Product(s) : Vosilasarm
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ellipses Pharma
Deal Size : Undisclosed
Deal Type : Divestment